AKEBIA THERAPEUTICS INC's ticker is AKBA and the CUSIP is 00972D105. A total of 80 filers reported holding AKEBIA THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $179,317 | -44.3% | 175,802 | 0.0% | 0.00% | -100.0% |
| Q1 2024 | $321,717 | +42.5% | 175,802 | -3.4% | 0.00% | – |
| Q4 2023 | $225,755 | +5.5% | 182,061 | -3.0% | 0.00% | – |
| Q3 2023 | $214,034 | +23.9% | 187,750 | -0.6% | 0.00% | – |
| Q2 2023 | $172,767 | +63.3% | 188,818 | 0.0% | 0.00% | – |
| Q1 2023 | $105,812 | -4.5% | 188,818 | -1.6% | 0.00% | – |
| Q4 2022 | $110,772 | +84.6% | 191,983 | -2.0% | 0.00% | – |
| Q3 2022 | $60,000 | -23.1% | 195,915 | -13.2% | 0.00% | – |
| Q2 2022 | $78,000 | -57.1% | 225,640 | -11.8% | 0.00% | – |
| Q1 2022 | $182,000 | -74.5% | 255,967 | -19.0% | 0.00% | -100.0% |
| Q4 2021 | $713,000 | -39.0% | 316,047 | -22.3% | 0.00% | -50.0% |
| Q3 2021 | $1,169,000 | -32.7% | 406,680 | -11.4% | 0.00% | -33.3% |
| Q2 2021 | $1,738,000 | +13.6% | 459,080 | +1.5% | 0.00% | 0.0% |
| Q1 2021 | $1,530,000 | +23.2% | 452,409 | +1.9% | 0.00% | +50.0% |
| Q4 2020 | $1,242,000 | +156.6% | 443,789 | +128.8% | 0.00% | +100.0% |
| Q3 2020 | $484,000 | -86.7% | 193,977 | -27.6% | 0.00% | -87.5% |
| Q2 2020 | $3,632,000 | +312.7% | 267,888 | +130.7% | 0.01% | +300.0% |
| Q1 2020 | $880,000 | +22.9% | 116,120 | +2.4% | 0.00% | +100.0% |
| Q4 2019 | $716,000 | +62.0% | 113,361 | +110.1% | 0.00% | 0.0% |
| Q1 2019 | $442,000 | +52.9% | 53,960 | +3.1% | 0.00% | 0.0% |
| Q4 2018 | $289,000 | +7.8% | 52,332 | +72.0% | 0.00% | 0.0% |
| Q3 2018 | $268,000 | +13.6% | 30,432 | +29.1% | 0.00% | – |
| Q2 2018 | $236,000 | -46.4% | 23,572 | -49.0% | 0.00% | -100.0% |
| Q1 2018 | $440,000 | -28.1% | 46,209 | +16.8% | 0.00% | 0.0% |
| Q4 2017 | $612,000 | -59.9% | 39,546 | -49.1% | 0.00% | -66.7% |
| Q3 2017 | $1,527,000 | +51.8% | 77,640 | +10.8% | 0.00% | +50.0% |
| Q2 2017 | $1,006,000 | +22.2% | 70,069 | -21.7% | 0.00% | 0.0% |
| Q1 2017 | $823,000 | +641.4% | 89,467 | +734.2% | 0.00% | – |
| Q4 2016 | $111,000 | – | 10,725 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Consonance Capital Management LP | 7,121,283 | $53,979,000 | 4.02% |
| DAFNA Capital Management LLC | 853,538 | $6,470,000 | 2.70% |
| Baupost Group | 17,527,968 | $132,862,000 | 1.96% |
| Nantahala Capital Management | 6,559,478 | $49,721,000 | 1.86% |
| Novo Holdings A/S | 3,393,039 | $25,719,000 | 1.72% |
| Abrams Capital Management | 5,656,462 | $42,876,000 | 1.69% |
| Stanley-Laman Group, Ltd. | 319,073 | $2,419,000 | 0.73% |
| Integral Health Asset Management, LLC | 200,000 | $1,516,000 | 0.67% |
| KNOTT DAVID M | 135,169 | $1,025,000 | 0.65% |
| Leap Investments LP | 54,700 | $415,000 | 0.61% |